APA (7th ed.) Citation

Beaver, J. A., Tzou, A., Blumenthal, G. M., McKee, A. E., Kim, G., Pazdur, R., & Philip, R. (2017). An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies. Clinical cancer research, 23(6), 1368-1372. https://doi.org/10.1158/1078-0432.CCR-16-1098

Chicago Style (17th ed.) Citation

Beaver, Julia A., Abraham Tzou, Gideon M. Blumenthal, Amy E. McKee, Geoffrey Kim, Richard Pazdur, and Reena Philip. "An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies." Clinical Cancer Research 23, no. 6 (2017): 1368-1372. https://doi.org/10.1158/1078-0432.CCR-16-1098.

MLA (9th ed.) Citation

Beaver, Julia A., et al. "An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies." Clinical Cancer Research, vol. 23, no. 6, 2017, pp. 1368-1372, https://doi.org/10.1158/1078-0432.CCR-16-1098.